Authors: Blume, HH Schug, BS

Citation: Hh. Blume et Bs. Schug, Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?, EUR J DRUG, 25(1), 2000, pp. 41-48

Authors: Mazur, D Schug, BS Evers, G Larsimont, V Fieger-Buschges, H Gimbel, W Keilbach-Bermann, A Blume, HH

Citation: D. Mazur et al., Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation, INT J CL PH, 37(8), 1999, pp. 386-392

Authors: Heinrich-Nols, J Schug, BS Evers, G Larsimont, V Elze, M Blume, HH Lee, LS Crawford, F

Citation: J. Heinrich-nols et al., Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers, INT J CL PH, 37(3), 1999, pp. 153-158

Authors: Blume, HH Schug, BS

Citation: Hh. Blume et Bs. Schug, The biopharmaceutics classification system (BCS): Class III drugs - bettercandidates for BA/BE waiver?, EUR J PH SC, 9(2), 1999, pp. 117-121

Authors: Breithaupt-Grogler, K Niebch, G Schneider, E Erb, K Hermann, R Blume, HH Schug, BS Belz, GG

Citation: K. Breithaupt-grogler et al., Dose-proportionality of oral thioctic acid - coincidence of assessments via pooled plasma and individual data, EUR J PH SC, 8(1), 1999, pp. 57-65

Authors: Gleiter, CH Schreeb, KH Freudenthaler, S Thomas, M Elze, M Fieger-Buschges, H Potthast, H Schneider, E Schug, BS Blume, HH Hermann, R

Citation: Ch. Gleiter et al., Lack of interaction between thioctic acid, glibenclamide and acarbose, BR J CL PH, 48(6), 1999, pp. 819-825